Pan-cancer analysis of HOMER1 in hepatocellular carcinoma revealing diagnostic potential and immune landscape with experimental validation

Salvato in:
Dettagli Bibliografici
Pubblicato in:Discover Oncology vol. 16, no. 1 (Dec 2025), p. 1840
Autore principale: Yan, Guohong
Altri autori: Lu, Ziyan, Zhang, Jiakao, Wang, Xiang, Mo, Shutian, Wei, Yongguang, Chen, Meifeng, Liang, Jiaming, Han, Chuangye, Ye, Xinping
Pubblicazione:
Springer Nature B.V.
Soggetti:
Accesso online:Citation/Abstract
Full Text
Full Text - PDF
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

MARC

LEADER 00000nab a2200000uu 4500
001 3259433378
003 UK-CbPIL
022 |a 2730-6011 
022 |a 1868-8497 
022 |a 1868-8500 
024 7 |a 10.1007/s12672-025-03528-6  |2 doi 
035 |a 3259433378 
045 2 |b d20251201  |b d20251231 
100 1 |a Yan, Guohong  |u The First Affiliated Hospital of Guangxi Medical University, Department of Hepatobiliary Surgery, Nanning, China (GRID:grid.412594.f) 
245 1 |a Pan-cancer analysis of HOMER1 in hepatocellular carcinoma revealing diagnostic potential and immune landscape with experimental validation 
260 |b Springer Nature B.V.  |c Dec 2025 
513 |a Journal Article 
520 3 |a ObjectiveHomer scaffold protein 1 (HOMER1), a postsynaptic scaffold protein, regulates excitatory synapses and intracellular signaling and has been implicated in tumorigenesis. This study systematically evaluates the oncogenic roles of HOMER1 through pan-cancer bioinformatics analysis and functional validation in hepatocellular carcinoma (LIHC).MethodsMulti-omics data from The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Tumor Immune Estimation Resource 2.0 (TIMER 2.0), cBioPortal, UALCAN, and other public databases were integrated to analyze HOMER1 expression profiles, prognostic relevance, epigenetic modifications, and immune infiltration. Drug sensitivity was assessed using Gene Set Cancer Analysis Lite (GSCALite) and DrugBank databases. Protein-protein interaction networks were constructed using the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) and functionally annotated via Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) analyses. HOMER1 protein expression was validated by immunohistochemistry in LIHC tissues. Cellular assays, including Cell Counting Kit-8 (CCK-8), Transwell migration and invasion assays, wound healing assay, and quantitative polymerase chain reaction (qPCR), were performed to investigate the effects of HOMER1 knockdown on LIHC cell proliferation, migration, and invasion.ResultsPan-cancer analysis revealed that HOMER1 exhibits cancer-type-specific dysregulation and is significantly associated with patient prognosis, DNA methylation, RNA modifications, immune cell infiltration, and immune checkpoint gene expression. HOMER1 expression correlated with anticancer drug sensitivity and was enriched in tumor-promoting pathways such as the peroxisome proliferator-activated receptor (PPAR) signaling pathway. In LIHC, HOMER1 was highly expressed, and its knockdown markedly suppressed hepatoma cell proliferation, migration, and invasion in vitro.ConclusionOur findings demonstrate that HOMER1 functions as a potential oncogene across multiple cancers and actively promotes malignant phenotypes in hepatocellular carcinoma. This study highlights HOMER1 as a promising prognostic biomarker and therapeutic target, providing new insights into cancer prognosis and immunotherapy strategies. 
653 |a DNA methylation 
653 |a Software 
653 |a Squamous cell carcinoma 
653 |a Epigenetics 
653 |a Medical prognosis 
653 |a Liver cancer 
653 |a Melanoma 
653 |a Antibodies 
653 |a Tumors 
653 |a Cell growth 
653 |a Mann-Whitney U test 
653 |a Proteins 
700 1 |a Lu, Ziyan  |u The First Affiliated Hospital of Guangxi Medical University, Department of Hepatobiliary Surgery, Nanning, China (GRID:grid.412594.f) 
700 1 |a Zhang, Jiakao  |u The First Affiliated Hospital of Guangxi Medical University, Department of Hepatobiliary Surgery, Nanning, China (GRID:grid.412594.f) 
700 1 |a Wang, Xiang  |u The First Affiliated Hospital of Guangxi Medical University, Department of Hepatobiliary Surgery, Nanning, China (GRID:grid.412594.f) 
700 1 |a Mo, Shutian  |u The First Affiliated Hospital of Guangxi Medical University, Department of Hepatobiliary Surgery, Nanning, China (GRID:grid.412594.f) 
700 1 |a Wei, Yongguang  |u The First Affiliated Hospital of Guangxi Medical University, Department of Hepatobiliary Surgery, Nanning, China (GRID:grid.412594.f) 
700 1 |a Chen, Meifeng  |u The First Affiliated Hospital of Guangxi Medical University, Department of Hepatobiliary Surgery, Nanning, China (GRID:grid.412594.f) 
700 1 |a Liang, Jiaming  |u The First Affiliated Hospital of Guangxi Medical University, Department of Hepatobiliary Surgery, Nanning, China (GRID:grid.412594.f) 
700 1 |a Han, Chuangye  |u The First Affiliated Hospital of Guangxi Medical University, Department of Hepatobiliary Surgery, Nanning, China (GRID:grid.412594.f) 
700 1 |a Ye, Xinping  |u The First Affiliated Hospital of Guangxi Medical University, Department of Hepatobiliary Surgery, Nanning, China (GRID:grid.412594.f) 
773 0 |t Discover Oncology  |g vol. 16, no. 1 (Dec 2025), p. 1840 
786 0 |d ProQuest  |t Health & Medical Collection 
856 4 1 |3 Citation/Abstract  |u https://www.proquest.com/docview/3259433378/abstract/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch 
856 4 0 |3 Full Text  |u https://www.proquest.com/docview/3259433378/fulltext/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch 
856 4 0 |3 Full Text - PDF  |u https://www.proquest.com/docview/3259433378/fulltextPDF/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch